Drug intelligence / Profile preview

OV-FV-01

Development stage: Preclinical
Lead developer: Protheragen
Modality: Oncolytic Viruses → Oncolytic Therapeutics
Administration: Intratumoral

Overview

OV-FV-01 is a preclinical-stage oncolytic virus therapy being developed by Protheragen for the treatment of various cancers. As an oncolytic virus, it is designed to selectively infect and replicate within tumor cells, leading to direct cell lysis and the subsequent release of tumor-associated antigens to stimulate a systemic anti-tumor immune response. While the specific viral backbone and molecular targets remain confidential, the program is part of Protheragen's portfolio of available therapeutic projects for oncology, positioned for licensing or collaborative development.

Beyond the preview

Go deeper on OV-FV-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OV-FV-01.

Explore the full profile